Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Taro Pharm Inds (TARO)

Taro Pharm Inds (TARO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,591,434
  • Shares Outstanding, K 37,587
  • Annual Sales, $ 572,950 K
  • Annual Income, $ 25,450 K
  • 60-Month Beta 0.61
  • Price/Sales 2.77
  • Price/Cash Flow 24.09
  • Price/Book 0.89
Trade TARO with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.31
  • Number of Estimates 1
  • High Estimate 0.31
  • Low Estimate 0.31
  • Prior Year 0.18
  • Growth Rate Est. (year over year) +72.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.45 +4.67%
on 03/06/24
42.44 -0.24%
on 03/21/24
+0.36 (+0.86%)
since 02/28/24
3-Month
40.45 +4.67%
on 03/06/24
45.76 -7.47%
on 01/26/24
+0.58 (+1.39%)
since 12/28/23
52-Week
22.89 +84.97%
on 03/29/23
45.76 -7.47%
on 01/26/24
+19.34 (+84.09%)
since 03/28/23

Most Recent Stories

More News
Taro: Fiscal Q3 Earnings Snapshot

Taro: Fiscal Q3 Earnings Snapshot

TARO : 42.34 (+0.19%)
Taro: Fiscal Q2 Earnings Snapshot

Taro: Fiscal Q2 Earnings Snapshot

TARO : 42.34 (+0.19%)
Taro: Fiscal Q1 Earnings Snapshot

Taro: Fiscal Q1 Earnings Snapshot

TARO : 42.34 (+0.19%)
Krensavage Asset Management Opposes Sun's Lowball Bid for Taro

/PRNewswire/ -- As the largest minority shareholder1 of Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Krensavage Asset Management LLC opposes Sun...

TARO : 42.34 (+0.19%)
Why Shares of Taro Pharmaceutical Are Rising Tuesday

The company is mulling a buyout offer from Sun Pharmaceutical.

TARO : 42.34 (+0.19%)
Taro: Fiscal Q4 Earnings Snapshot

Taro: Fiscal Q4 Earnings Snapshot

TARO : 42.34 (+0.19%)
Taro Pharmaceutical (TARO) Lags Q3 Earnings and Revenue Estimates

Taro (TARO) delivered earnings and revenue surprises of -78.16% and 14.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

TARO : 42.34 (+0.19%)
CTLT : 56.45 (-0.05%)
Taro Provides Results for December 31, 2022

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the quarter and nine months ended December 31, 2022.

TARO : 42.34 (+0.19%)
Taro to Release Third Quarter Results on January 24, 2023

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the third quarter ended December 31, 2022, after the close of market on Tuesday, January...

TARO : 42.34 (+0.19%)
Taro Pharmaceutical (TARO) Reports Q2 Loss, Misses Revenue Estimates

Taro (TARO) delivered earnings and revenue surprises of -108.33% and 18.96%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

TARO : 42.34 (+0.19%)
SCYX : 1.4700 (+3.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Taro Pharmaceutical Industries is engaged in the production, research and development, and marketing of prescription and over-the-counter pharmaceutical products, with a focus on generic products. In addition to the production of finished dosage form drugs, they also synthesize the pharmaceutical chemicals...

See More

Key Turning Points

3rd Resistance Point 42.64
2nd Resistance Point 42.50
1st Resistance Point 42.42
Last Price 42.34
1st Support Level 42.20
2nd Support Level 42.06
3rd Support Level 41.98

See More

52-Week High 45.76
Last Price 42.34
Fibonacci 61.8% 37.02
Fibonacci 50% 34.32
Fibonacci 38.2% 31.63
52-Week Low 22.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar